圣湘生物科技股份有限公司 内部控制审计报告 众环审字(2025)1100092号 圣湘生物科技股份有限公司全体股东: 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制，并评价其有效性是圣湘生物公司董事会的责任。 内部控制审计报告 众环审字(2025)1100092 号 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了圣 湘生物科技股份有限公司（以下简称"圣湘生物公司"）2024 年 12 月 31 日的财务报告内部 控制的有效性。 一、圣湘生物公司对内部控制的责任 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 中审众 通合伙) 中国注册会计师: 中国注册会计师 ...

圣湘生物科技股份有限公司 审 计 报 告 众环审字(2025)1100091号 审计报告 众环审字(2025)1100091 号 圣湘生物科技股份有限公司全体股东: 一、审计意见 我们审计了圣湘生物科技股份有限公司(以下简称"圣湘生物公司")财务报表,包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、合并及公司 现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 圣湘生物公司 2024 年 12 月 31 日合并及公司的财务状况以及 2024 年度合并及公司的经营成 果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则,我们独立于圣湘生物公司,并履行了职业道德方面的其他责任。我们相信,我 们获取的审计证据是充分、适当的,为发表审计意见提供了基础。 三、关键审计事项 关键审计事项是我们根据职业判断,认为对本期财务报表审计最为重 ...

| 名称 持有数量(万股) | | 占总股本比例 (%) | 增减情况(万 | | --- | --- | --- | --- | | | | | 股) | | 戴立忠 | 19020.51 | 32.66 | 不变 | | 湖南圣维投资管理有限公司 | 3719.66 | 6.39 | 不变 | | 陈文义 | 3291.74 | 5.65 | 不变 | | 华宝中证医疗ETF | 1151.44 | 1.98 | 新进 | | 朱锦伟 | 1109.86 | 1.91 | -512.47 | | 易方达医疗保健行业混合A | 1049.03 | 1.80 | -563.10 | | 上海迎水投资管理有限公司-迎水绿洲16号私募证券 投资基金 | 965.24 | 1.66 | -107.61 | | 湖南圣维鼎立管理咨询中心(有限合伙) | 756.71 | 1.30 | 不变 | | 湖南圣维华宁管理咨询中心(有限合伙) | 726.75 | 1.25 | 不变 | | 刘欲晓 | 639.96 | 1.10 | 新进 | | 较上个报告期退出前十大股东有 | | | | | 香港中央结算有限公司 | ...

圣湘生物科技股份有限公司 2024 年度独立董事述职报告 （王善平） 各位股东及股东代表： 二、独立董事年度履职概况 （一）会议出席情况 报告期内，公司共召开董事会 10 次，本人均参加了所有应参加的董事会会 议，无缺席和委托其他董事出席董事会的情况；共召开股东大会 3 次，本人出席 了 3 次股东大会。作为独立董事参与独立董事专门会议 2 次，作为审计委员会主 任委员以及薪酬与考核委员会委员,参加了审计委员会会议 4 次，薪酬与考核委 员会会议 4 次。 本人王善平，作为圣湘生物科技股份有限公司（以下简称"公司"）的独立董 事，2024 年度，严格按照《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司独立董事管 理办法》《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"） 等有关法律法规及《公司章程》《独立董事工作制度》等相关制度的规范要求， 本着对全体股东认真负责的态度，认真、忠实、勤勉地履行工作职责，客观、独 立和公正地参与公司决策，充分发挥独立董事作用，切实维护公司整体利益和全 体股东特别是中小股东的合法权益。 现将 2024 ...

圣湘生物科技股份有限公司 2024 年度独立董事述职报告 （曹亚） 各位股东及股东代表： 作为圣湘生物科技股份有限公司（以下简称"公司"）的独立董事，2024 年 度，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中华 人民共和国证券法》（以下简称"《证券法》"）《上市公司独立董事管理办法》 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）等有关法 律法规及《公司章程》《独立董事工作制度》等相关制度的规范要求，本着对全 体股东认真负责的态度，认真、忠实、勤勉地履行工作职责，客观、独立和公正 地参与公司决策，充分发挥独立董事作用，切实维护公司整体利益和全体股东特 别是中小股东的合法权益。 现将 2024 年度履行独立董事职责的具体情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 本人曹亚，1951 年 2 月出生，硕士研究生学历。1973 年至 1977 年就读中南 大学湘雅医学院（原湖南医科大学）临床医学专业（本科），1978 年至 1981 年 就读中南大学湘雅医学院实验肿瘤学专业。1981 年至今任职于中南大学湘雅医 学院，历任讲师、助教、 ...

（乔友林） 圣湘生物科技股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 作为圣湘生物科技股份有限公司（以下简称"公司"）的独立董事，2024 年 度，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司独立董事管理办 法》《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）等 有关法律法规及《公司章程》《独立董事工作制度》等相关制度的规范要求，本 着对全体股东认真负责的态度，认真、忠实、勤勉地履行工作职责，客观、独立 和公正地参与公司决策，充分发挥独立董事作用，切实维护公司整体利益和全体 股东特别是中小股东的合法权益。 现将 2024 年度履行独立董事职责的具体情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 本人乔友林，1955 年 4 月出生，博士研究生学历。1980 年至 1983 年，就读 大连医学院医学硕士；1986 年至 1989 年，于美国国立卫生研究院国家癌症研究 所担任访问学者；1990 年至 1996 年，就读美国约翰斯.霍普金斯大学预防医学博 士。199 ...

圣湘生物科技股份有限公司 作为公司的独立董事，本人及直系亲属、主要社会关系均不在公司及其附属 企业任职，与公司其他董事、监事、高级管理人员、实际控制人之间不存在关联 关系，具有《上市公司独立董事管理办法》《公司章程》及《独立董事工作制度》 所要求的独立性和担任公司独立董事的任职资格，能够确保客观、独立的专业判 断，不存在影响独立性的情况。 2024 年度独立董事述职报告 （肖朝君） 各位股东及股东代表： 作为圣湘生物科技股份有限公司（以下简称"公司"）的独立董事，2024 年 度，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司独立董事管理办 法》《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）等 有关法律法规及《公司章程》《独立董事工作制度》等相关制度的规范要求，本 着对全体股东认真负责的态度，认真、忠实、勤勉地履行工作职责，客观、独立 和公正地参与公司决策，充分发挥独立董事作用，切实维护公司整体利益和全体 股东特别是中小股东的合法权益。 现将 2024 年度履行独立董事职责的具体情况汇报如下： 一、独立董事的基本情 ...

Financial Performance - The company's sales reached ¥512,108,285.84, representing a year-on-year increase of 26.60% compared to ¥404,497,043.91 in the same period last year[4]. - Operating revenue for the quarter was ¥475,488,325.65, up 21.62% from ¥390,946,762.39 in the previous year[4]. - Net profit attributable to shareholders was ¥91,735,483.67, reflecting a 13.22% increase from ¥81,024,703.84 year-on-year[4]. - Total revenue for Q1 2025 reached CNY 475,488,325.65, an increase of 21.6% compared to CNY 390,946,762.39 in Q1 2024[17]. - Net profit for Q1 2025 was CNY 80,633,918.47, compared to CNY 73,410,291.06 in Q1 2024, representing a growth of 9.3%[18]. - The net profit attributable to the parent company shareholders for Q1 2025 was approximately ¥91.74 million, an increase from ¥81.02 million in Q1 2024, representing a growth of 13.4%[19]. - The total comprehensive income for Q1 2025 was approximately ¥80.80 million, compared to ¥75.33 million in Q1 2024, reflecting an increase of 7.3%[19]. - The basic and diluted earnings per share for Q1 2025 were both ¥0.16, up from ¥0.14 in Q1 2024, indicating a 14.3% increase[19]. Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of ¥33,816,646.47, a 73.09% reduction compared to a net outflow of ¥125,646,118.28 in the previous year[4][7]. - Cash inflows from operating activities in Q1 2025 totaled approximately ¥384.53 million, down from ¥460.01 million in Q1 2024, a decrease of 16.4%[22]. - The net cash flow from operating activities for Q1 2025 was negative at approximately -¥33.82 million, an improvement from -¥125.65 million in Q1 2024[22]. - Cash outflows from investing activities in Q1 2025 amounted to approximately ¥843.48 million, compared to ¥762.88 million in Q1 2024, an increase of 10.6%[23]. - The net cash flow from investing activities for Q1 2025 was negative at approximately -¥587.50 million, worsening from -¥208.22 million in Q1 2024[23]. - Cash inflows from financing activities in Q1 2025 were approximately ¥823.30 million, significantly higher than ¥426.07 million in Q1 2024, marking an increase of 93.2%[23]. - The net cash flow from financing activities for Q1 2025 was approximately ¥408.14 million, slightly down from ¥421.06 million in Q1 2024[23]. - The ending cash and cash equivalents balance for Q1 2025 was approximately ¥4.26 billion, a slight increase from ¥4.25 billion in Q1 2024[23]. Assets and Liabilities - Total assets increased by 12.56% to ¥9,684,304,892.36 from ¥8,603,796,143.70 at the end of the previous year[5]. - Total assets increased to CNY 9,684,304,892.36 as of March 31, 2025, from CNY 8,603,796,143.70 at the end of 2024[15]. - Total liabilities rose to CNY 2,251,421,445.81 as of March 31, 2025, compared to CNY 1,258,010,592.97 at the end of 2024[15]. - Non-current assets totaled CNY 3,908,114,618.51 as of March 31, 2025, up from CNY 2,814,236,319.40 at the end of 2024[14]. - The company reported a significant increase in fixed assets, which rose to CNY 1,217,392,222.99 from CNY 1,091,496,466.67[14]. - The company’s long-term borrowings increased to CNY 810,162,419.18 as of March 31, 2025, compared to CNY 396,646,274.01 at the end of 2024[15]. - The company’s total equity as of March 31, 2025, was CNY 7,432,883,446.55, slightly up from CNY 7,345,785,550.73 at the end of 2024[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,629[9]. - The largest shareholder, Dai Lizhong, holds 32.83% of the shares, totaling 190,205,090 shares[10]. Research and Development - Research and development expenses totaled ¥61,266,076.45, accounting for 12.88% of operating revenue, down from 16.35% in the previous year[5]. Return on Equity - The weighted average return on equity rose to 1.26%, an increase of 0.14 percentage points from 1.12%[4]. - The company reported non-recurring gains of ¥1,237,647.73 for the period, after accounting for tax effects and minority interests[6].

Financial Performance - The company has not yet achieved profitability since its listing[3]. - Sansure Biotech reported a significant increase in revenue, achieving a year-over-year growth of 25% in Q3 2023[15]. - The company achieved operating revenue of CNY 1,458,061,552.96 in 2024, representing a year-on-year growth of 44.78%[22]. - The net profit attributable to shareholders of the listed company was CNY 275,596,143.87, a decrease of 24.23% compared to the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 182.25% to CNY 202,227,363.25[22]. - The net cash flow from operating activities reached CNY 274,447,856.11, marking a significant increase of 530.34%[22]. - Basic earnings per share decreased by 24.19% to CNY 0.47, while diluted earnings per share remained the same[23]. - The company achieved a revenue of 308.6 million RMB in the immunodiagnostic market in 2023, reflecting a year-on-year growth of 10.4%[88]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a 25% year-over-year growth[167]. Dividend Policy - The company plans to distribute a cash dividend of 2.75 RMB per 10 shares (including tax), totaling approximately 157.9 million RMB based on the current total share capital of 579,388,006 shares, after deducting 5,209,401 shares in the repurchase account[5]. - The company plans to implement annual cash dividends of no less than 300 million yuan over the next three years, having already distributed a total of over 2.2 billion yuan in dividends since its listing[48]. - For the 2023 fiscal year, the company distributed a cash dividend of RMB 2.00 per 10 shares, and for the 2024 fiscal year, it plans to distribute RMB 2.75 per 10 shares[191]. - The cash dividend amount (including tax) distributed was CNY 301,329,669.63, which represents 109.34% of the net profit attributable to ordinary shareholders[195]. Research and Development - The company is investing heavily in R&D, with a budget allocation of 15% of total revenue towards the development of next-generation sequencing technologies[16]. - The company's R&D investment accounted for 24.79% of operating revenue, reflecting a strategic focus on innovation[23]. - R&D investment for 2024 totaled CNY 361.38 million, up 53.36% year-on-year, accounting for 24.79% of operating revenue[34]. - The company has filed 359 new patents during the reporting period, including 154 invention patents, and has a total of 1,253 patents[78]. - The company is focusing on new technologies such as multi-PCR, NGS, and CRISPR, aiming for simplification, automation, and systematization in molecular diagnostics[65]. - The company has developed multiple detection technologies, including tNGS, mNGS, and WGS, significantly improving clinical diagnosis efficiency and accuracy in areas such as tuberculosis and respiratory infections[73]. Market Expansion and Strategy - Sansure Biotech plans to enter new international markets, targeting a 20% increase in overseas sales by the end of 2024[16]. - The company is actively pursuing internationalization and innovation-driven strategies, particularly in key areas such as respiratory, maternal and child health, blood source, and sequencing technologies[22]. - The company is exploring potential acquisitions to strengthen its market position, with a focus on companies in the biotech sector[167]. - The company has established overseas subsidiaries in countries such as Indonesia, France, the UK, and the US, expanding its global footprint to over 160 countries[97]. - The company is focusing on enhancing its core technologies in molecular diagnostics, including high-precision "magnetic bead method" and "POCT mobile molecular diagnostics"[91]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Zhongchao Zhonghuan Accounting Firm[4]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company adheres to a strict governance framework in compliance with relevant laws and regulations[156]. - The audit committee confirmed the accuracy and completeness of the annual and quarterly reports, ensuring no false statements or omissions[178]. Risk Management - The company has detailed various risks and countermeasures in its annual report, which investors should review[3]. - The company faces risks related to market competition, quality control, and potential changes in government policies affecting tax incentives and subsidies[103][104]. Talent and Workforce - The company has introduced nearly 20 PhD graduates from renowned domestic and international universities in 2024 to enhance its talent pool[43]. - The number of R&D personnel increased to 581, accounting for 24.77% of the total workforce, with an average salary of 20.29 million RMB[90]. - The company has established a training program to enhance employee skills and promote leadership development through its "Saint Xiang Higher School"[187]. Social Responsibility - The company has donated over 400 million yuan in cash and materials for public health events and disaster relief efforts[47]. - The company has been recognized with the "National Public Health Contribution Award" for its cervical cancer HPV screening project in Sierra Leone[41]. Stock Incentives - The company has implemented stock incentives for various personnel, with values ranging from 8.05 to 230.92[162]. - The total number of stock incentives granted during the reporting period was 257,655 units, with a total value of 308,387[162]. - The company continues to expand its stock incentive programs to attract and retain talent in key positions[162].

根据《中华人民共和国公司法》《中华人民共和国证券法》《国有企业、上 市公司选聘会计师事务所管理办法》《关于上市公司做好选聘会计师事务所工作 的提醒》等法律法规的要求，圣湘生物科技股份有限公司（以下简称"公司"）对 中审众环会计师事务所（特殊普通合伙）（以下简称"中审众环"）2024 年度审 计过程中的履职情况进行了评估，具体情况如下： 一、资质条件 1．机构名称：中审众环会计师事务所（特殊普通合伙） 2．成立日期：中审众环始创于 1987 年，是全国首批取得国家批准具有从事 证券、期货相关业务资格及金融业务审计资格的大型会计师事务所之一。根据财 政部、证监会发布的从事证券服务业务会计师事务所备案名单，本所具备股份有 限公司发行股份、债券审计机构的资格。2013 年 11 月，按照国家财政部等有关 要求转制为特殊普通合伙制。 3．组织形式：特殊普通合伙企业 4．注册地址：湖北省武汉市武昌区水果湖街道中北路 166 号长江产业大厦 17-18 层。 5．首席合伙人：石文先 圣湘生物科技股份有限公司 关于 2024 年度会计师事务所履职情况评估报告 8．2024 年度上市公司审计客户家数 244 家，主要行业涉及制 ...